- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Lawrence True addresses the sampling issue in prostate cancer diagnosis, focusing specifically on biopsy results. Biographies: Lawrence True, MD, Pathologist, University of Washington, Seattle, WA Related Content: Pathology Perspective: CG1 is Still Cancer "Presentation" - Theodorus van der Kwast...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Alastair Lamb hosts two speakers who explore the nuances of breast cancer diagnosis and treatment in relation to the broader debate about cancer classification. Biographies: Alastair Lamb, FRCS (Urol), PhD, MBChB, MA, Associate Professor, Nuffield Department of Surgical Sciences, Oxford Universit...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Alastair Lamb discusses the molecular basis of prostate cancer behavior using spatial transcriptomics. He demonstrates how this technique creates high-resolution clonal maps of prostates, revealing transcriptomic and genomic information at near-cellular levels while preserving tissue structure. B...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Daniel Lin discusses the implications of potentially reclassifying Grade Group 1 prostate cancer as non-cancer in the context of active surveillance. Dr. Lin highlights the current understanding of grade reclassification as a primary driver in active surveillance decisions, noting that upgrading...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Laurence Klotz discusses the challenges and pitfalls in active surveillance for prostate cancer. He highlights the dual goals of avoiding unnecessary treatment while identifying patients who would benefit from intervention. Dr. Klotz addresses issues leading to overtreatment, such as overgrading,...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Declan Murphy discusses the impact of widespread MRI use on Grade Group 1 prostate cancer diagnosis in Australia. He highlights that since the introduction of fully funded MRI access in 2018, the proportion of newly diagnosed Grade Group 1 cancers has dropped from 40% to less than 20%. Dr. Murphy...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Caroline Moore discusses the differences between active surveillance and watchful waiting in prostate cancer management. Dr. Moore highlights that MRI-led pathways have reduced the diagnosis of low-risk prostate cancers in England, similar to Australia's experience. She concludes by questioning w...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Andrew Vickers addresses concerns about underdiagnosing low-volume Grade Group 2 prostate cancer when considering the reclassification of Grade Group 1. He argues that the benefits of reducing overdiagnosis and overtreatment outweigh speculative risks. Dr. Vickers concludes by emphasizing the nee...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Ruth Etzioni discusses the potential role of modeling in evaluating the implications of relabeling Grade Group 1 prostate cancer. She emphasizes that while models cannot yet provide definitive answers, they can help compare different scenarios. Dr. Etzioni concludes that properly specifying these...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Andrew Vickers addresses concerns about underdiagnosing low-volume Grade Group 2 prostate cancer when considering reclassification of Grade Group 1. He argues that many objections to redesignation are speculative and fail to consider the current problems of overdiagnosis, overtreatment, and patie...
|
